Chemotherapy of malignant fibrous histiocytoma: a Southwest Oncology Group report

Cancer. 1977 Nov;40(5):2010-4. doi: 10.1002/1097-0142(197711)40:5<2010::aid-cncr2820400504>3.0.co;2-1.

Abstract

Malignant fibrous histiocytoma is a rare tumor, which constitutes 3-4% of the soft tissue sarcomas. It occurs with maximum frequency in the sixth and seventh decades of life and has a distinct male preponderance. In two-thirds of the patients an extremity is the primary site and approximately one-half develop local recurrences and one-half, distant metastases. Response to combination chemotherapy occurred in 33%, a rate similar to that seen in other sarcomas.

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic
  • Drug Therapy, Combination
  • Evaluation Studies as Topic
  • Female
  • Histiocytoma, Benign Fibrous / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Soft Tissue Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents